

DAFTAR PUSTAKA

1. Dorland WA N. Kamus saku kedokteran dorland. Jakarta: EGC; 2011. 173 p.
2. WHO. Cancer [Internet]. 2018. Available from: <https://www.who.int/news-room/fact-sheets/detail/cancer>
3. Badan Penelitian dan Pengembangan Kesehatan. Riset kesehatan dasar (Riskesdas) [Internet]. 2018. Available from: <https://www.litbang.kemkes.go.id/hasil-utama-riskesdas-2018/>
4. Bray F, Ferlay J, Soerjomataram I. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. 2018;394–424.
5. WHO. Global cancer observatory [Internet]. 2018. Available from: <https://gco.iarc.fr/today/online-analysis-multi-bars>
6. Rambe IR, Asri A. Artikel penelitian profil tumor ganas ovarium di laboratorium patologi anatomi fakultas kedokteran universitas andalas periode januari 2011 sampai desember 2012. 2014;3(1):54–7.
7. Luhuria FD, Friadi A. Comparison of the risk malignancy index value of ovarian cancer serosum and musinosum type Dr . M . Djamil Padang in 2017. 2020;87–94.
8. Koshiyama M, Matsumura N, Konishi I. Recent concepts of ovarian carcinogenesis : type I and type II. 2014;2014.
9. Tahun BL, Arania R, Windarti I. Karakteristik pasien kanker ovarium di Rumah Sakit Dr . H . Abdul Moeloek ovarian cancer characteristic in H . Abdul Moeloek hospital Bandar Lampung 2009-2013 period. 2015;2–6.
10. Lengyel E. Ovarian cancer development and metastasis. Am J Pathol [Internet]. 2010;177(3):1053–64. Available from: <http://dx.doi.org/10.2353/ajpath.2010.100105>
11. Chang L, Huang C, Lai M, Shen L, Wu FL. Prognostic factors in epithelial ovarian cancer : A population-based study. 2018;1–11.
12. Berek JS, Hacker NF, Hengst T. Gynecologic oncology. 6th ed.
13. Budiana ING. Tumor ovarium : prediksi keganasan prabedah. 2013;4:179–85.
14. Rujuta J, Nandita M. Risk of malignancy index (RMI) in evaluation of adnexal mass. 2014;
15. Moolthiya W, Yuenyao P. The risk of malignancy index (RMI) in diagnosis of ovarian malignancy. 2009;10:865–8.
16. Putri IA. Perbandingan rerata skor RMI pada kanker epitel ovarium stadium awal dengan stadium lanjut. Universitas Andalas; 2017.
17. Paulsen F, Waschke J. Atlas anatomi manusia sobotta jilid 2: organ-organ dalam. 23rd ed. EGC; 2010.

18. Snell RS. Anatomi klinis berdasarkan sistem. Jakarta: Penerbit Buku Kedokteran EGC; 2012. 492–495 p.
19. Mescher AL. Histologi dasar junqueira teks & atlas. 12th ed. Jakarta: Penerbit Buku Kedokteran EGC; 2012. 147–150 p.
20. Harsono AB. Kanker ovarium: the silent killer. *Indones J Obstet Gynecol Sci.* 2020;1–6.
21. Made N, Suastari P. Pemeriksaan radiologi untuk deteksi kanker ovarium. 2018;45(4):298–302.
22. Rosen DG, Yang G, Liu G, Mercado-uribe I, Chang B, Xiao XS, et al. Department of pathology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77005-4095. 2009;(1):2089–102.
23. Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review Pathologic classification of OC. 2017;9–32.
24. Busmar B. Buku acuan nasional onkologi ginekologi. Jakarta: Yayasan Bina Pustaka Sarwono Prawirohardjo; 2010. 468–524 p.
25. Miaskowski C, Aouizerat BE, Chen L, Dodd MJ. Epidemiological and genetic factors associated with ovarian cancer. 2009;32(4):281–8.
26. Dhitayoni IA, Budiana ING. Profil pasien kanker ovarium di rumah sakit umum pusat sanglah Denpasar – Bali periode juli 2013 – juni 2014. 2017;6(3):1–9.
27. American Cancer Society. Cancer Facts & Figures 2018. 2018;
28. Strauss JF, Alvarez RD, Bowen DJ, Cho KR, Donovan H, Duquette D. Ovarian cancers: evolving paradigms in research and care. Washington, DC: The National Academies Press; 2016.
29. Mok SC, Kwong J, Welch WR, Samimi G, Ozbun L. Etiology and pathogenesis of epithelial ovarian cancer. 2007;23:367–76.
30. Fathalla MF. Incessant ovulation and ovarian cancer – a hypothesis revisited. 2013;5(4):292–7.
31. Smith ER, Xu X. Ovarian ageing , follicle depletion , and cancer: a hypothesis for the aetiology of epithelial ovarian cancer involving follicle depletion. *Lancet Oncol* [Internet]. 2008;9(11):1108–11. Available from: [http://dx.doi.org/10.1016/S1470-2045\(08\)70281-X](http://dx.doi.org/10.1016/S1470-2045(08)70281-X)
32. Desai A, Xu J, Aysola K, Qin Y, Okoli C, Hariprasad R. Epithelial ovarian cancer: An overview. 2014;3(1):1–8.
33. Kurman RJ, Shih IM. The origin and pathogenesis of epithelial ovarian cancer: A proposed unifying theory. *Am J Surg Pathol.* 2010;34(3):433–43.
34. Kurman RJ. Pathogenesis of ovarian cancer : Lessons from morphology and molecular biology and their clinical implications. 2008;151–60.
35. Doubeni CA, Doubeni ARB, Myers AE. Diagnosis and management of ovarian cancer. 2016;

36. Aktürk E, Karaca RE, Alanbay I, Dede M, Kardeşahin E, Yenen MC, et al. Comparison of four malignancy risk indices in the detection of malignant ovarian masses. *J Gynecol Oncol.* 2011;22(3):177–82.
37. Suryantara B. Perbandingan risk of malignancy index (RMI) 4 dan 3 sebagai uji diagnostik keganasan tumor ovarium. Universitas Gadjah Mada; 2012.
38. Triana E. Perbandingan akurasi modifikasi risk of malignancy index (RMI) dan risk of malignancy index (RMI) dalam prediksi keganasan tumor ovarium tipe epitel. Universitas Andalas; 2018.
39. Aditiyono, Harsono AB, Herman S. CA 125 dan risk of malignancy index (RMI)2 sebagai prediktor keganasan tumor ovarium tipe epitel. 2018;11(1):18–30.
40. Putri FH. Hubungan kadar CA-125 dengan gambaran histopatologi pasien kanker ovarium epitelial di RSUP Dr. M Djamil. Universitas Andalas; 2019.
41. Dwi ariningtyas N. CA 125 dan pemakaian klinis dalam penatalaksanaan kanker ovarium. *Qanun Med - Med J Fac Med Muhammadiyah Surabaya.* 2018;2(2):73–82.
42. Davis SR, Lambrinoudaki I, Lumsden M, Mishra GD, Pal L, Rees M, et al. Menopause. *Nat Rev Dis Prim.* 2015;1:1–19.
43. Burges A, Schmalfeldt B. Ovarialkarzinom: dagnostik und therapie. *Dtsch Arztebl.* 2011;108(38):635–41.
44. Rhaazi N Al, Mulawardhana P, Atika. Karakteristik kanker ovarium tipe epitel yang menjalani operasi di departemen obstetri dan ginekologi RSUD Dr. Soetomo tahun 2015. Universitas Airlangga; 2018.
45. Choi JH, Wong AST, Huang HF, Leung PCK. Gonadotropins and ovarian cancer. *Endocr Rev.* 2007;28(4):440–61.
46. Johari A Bin, Siregar FG. Insidensi kanker ovarium berdasarkan faktor risiko di RSUP Haji Adam Malik tahun 2008-2011. *E-Jurnal FK USU.* 2013;1(1):1–6.
47. Scholler N, Urban N, Gene CA. CA125 in ovarian cancer. 2010;1(4):513–23.
48. Rauh-hain JA, Krivak TC, Carmen MG, Olawaiye AB. Ovarian cancer screening and early detection in the general population. 2011;4(1):15–21.
49. Fleischer AC, Lyshchik A, Hirari M, Moore RD, Abramson RG, Fishman DA. Early detection of ovarian cancer with conventional and contrast-enhanced transvaginal sonography: recent advances and potential improvements. 2012;2012.
50. Yip P, Chen T, Sessaiah P, Stephen LL, Michael-ballard KL, James P, et al. Comprehensive serum profiling for the discovery of epithelial ovarian cancer biomarkers. 2011;6(12):1–10.